Posted On: 01/03/2015 4:33:23 PM
Post# of 30034
Lympro's closest competitor may be Nanosomix's "Envision" blood test for AD. As I understand it, the Envision blood test can detect the same p-tau that was previously only detectable in cerebrospinal fluid via painful spinal tap. In September, Nanosomix promised to make their AD test available for clinical trials in "the Fall." They've been getting some nice coverage in recent months, possibly a factor in GC's decision to present the LP002 data to a captive scientific audience this month. Nanosomix is working on other AD blood tests as well, they're a private company ... just wondering out loud now if they might be interested in adding Lympro to their portfolio to try to corner the market on AD blood tests.
Pay to view article about Envision from Dec. 16 2014:
Pay to view article about Envision from Dec. 16 2014:
Quote:
Executive Summary
Envision a simple blood test that can detect the presence of Alzheimer’s disease up to 10 years in advance of a standard clinical diagnosis. NanoSomiX Inc. is developing technology that evaluates brain-derived exosomes and reveals biological changes that are implicated in the pathogenesis of AD. https://www.pharmamedtechbi.com/publications/...-detection
Quote:
These early findings indicate that the blood-based neural-protein assay developed by NanoSomiX is a significant advance for those conducting AD related research and drug development. Possible uses include the ability to identify early preclinical AD cases in the effort to guide therapy, serve as a prognostic tool to detect at-risk patients, and to provide a reliable biomarker in clinical trials for stratification of patients, monitoring, end point determination, etc.
NanoSomiX is currently seeking research and business partners to further develop the technology, claims, and utility of this assay. http://www.nanosomix.com/technology
Quote:
The first assay panel offered by NanoSomiX includes tests for amyloid beta 1-42, total tau, p-tau T181, p-tau S396, as well as exosome marker CD81. A second assay panel that measures insulin resistance as an indication of early AD onset is under development. Additional assay panels focused on neurodegerative, neuroinflammatory and neurotraumatic disease states are planned for the future. NanoSomiX is also offering neuron-derived exosome isolation in serum and plasma samples as a service to researchers that would like to conduct their own biomarker research. http://www.nanosomix.com/overview
(0)
(0)Scroll down for more posts ▼
